Recent news has emerged that Dong-A Socio Holdings will absorb its subsidiary Dong-A Pharmaceutical, transitioning to a business holding company structure. This merger is attracting significant attention in the pharmaceutical industry and raising expectations for future changes.

Dong-A Socio Holdings' Merger Decision

On the 24th, Dong-A Socio Holdings resolved at a board meeting to absorb its 100% subsidiary, Dong-A Pharmaceutical. The merger is scheduled to take effect on October 1st. This merger will proceed as a small-scale transaction without the issuance of new shares, meaning there will be no changes to Dong-A Socio Holdings' shareholder composition or equity ratios after the merger is completed.

Background and Goals of the Merger

The background for this merger lies in the intensifying competition in the domestic and international healthcare markets. Dong-A Socio Holdings aims to strengthen Dong-A Pharmaceutical's competitiveness in the consumer healthcare market and internalize its stable cash-generating capabilities. This will facilitate a transition from a pure holding company to a business holding company structure that concurrently manages direct business operations, new group investments, the acquisition of new growth engines, and subsidiary management. This structure will enable the direct utilization of cash generated from Dong-A Pharmaceutical's business without the need for separate subsidiary dividends.

Dong-A Pharmaceutical's Growth Potential

Dong-A Pharmaceutical is leading growth in areas such as Bacchus, over-the-counter drugs, healthcare product lines, and derma-cosmetics, establishing itself as the group's cash cow. A representative from Dong-A Socio Holdings stated, "The holding company's revenue was limited to dividends and brand royalties, which constrained investment." They added, "We expect to accelerate new investments and the acquisition of new growth engines based on Dong-A Pharmaceutical's cash-generating capabilities."

Future Business Strategy

Following the merger, Dong-A Socio Holdings plans to further expand its overseas market presence by leveraging various business models, building upon the competitive brand value and core infrastructure accumulated by Dong-A Pharmaceutical. Specifically, the company intends to strengthen its market position through diversification of e-commerce channels, entry into global retail chains, and active brand collaborations.

The company mentioned, "The secured funds will be utilized for new drug development and bio investments," but declined to disclose specific investment areas or details, citing them as public disclosure matters. These changes are expected to have a positive impact on both Dong-A Socio Holdings and Dong-A Pharmaceutical.